QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease
Advances deployment of mRNA technology across vaccines and therapeutics development
It works as an adjunct to standard care based on robust clinical trials
Takeda Will Focus its Efforts on Dengue, Zika and Pandemic vaccines
WHO prequalification enables the procurement of ROTAVAC 5D by UN agencies namely UNICEF and PAHO
The contribution of Wockhardt at Wrexham is one of the best examples of the success and significant potential of India-UK partnerships in the healthcare sector
Winlevi has been approved by the United States FDA as a novel drug with a unique mechanism of action for the topical treatment of acne in patients 12 years and older
Subscribe To Our Newsletter & Stay Updated
